Oncotarget | Prognostic Markers in Adrenocortical Carcinoma

Oncotarget published this trending research paper on September 8, 2020, entitled, "GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3" by researchers from the Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; The Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA; Department of Surgery, Medical College of Wisconsin, Milwaukee, WI; Office of Science and Technology Resources, Frederick National Laboratory for Cancer Research, National Institutes of Health, Bethesda, MD; Salubris Biotherapeutics, Gaithersburg, MD.

DOI - https://doi.org/10.18632/oncotarget.27703

Correspondence to - Electron Kebebew - kebebew@stanford.edu

Abstract:
Recent evidence has implicated APOBEC3B (Apolipoprotein B mRNA editing enzyme catalytic subunit 3B) as a source of mutations in breast, bladder, cervical, lung, head, and neck cancers. However, the role of APOBEC3B in adrenocortical carcinoma (ACC) and the mechanisms through which its expression is regulated in cancer are not fully understood. Here, we report that APOBEC3B is overexpressed in ACC and it regulates cell proliferation by inducing S phase arrest. We show high APOBEC3B expression is associated with a higher copy number gain/loss at chromosome 4 and 8 and TP53 mutation rate in ACC. GATA3 was identified as a positive regulator of APOBEC3B expression and directly binds the APOBEC3B promoter region. Both GATA3 and APOBEC3B expression levels were associated with patient survival. Our study provides novel insights into the function and regulation of APOBEC3B expression in addition to its known mutagenic ability.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.c....om/details/email_upd

Press release - https://www.oncotarget.com/new....s/pr/gata3-and-apobe

Keywords - adrenocortical carcinoma, APOBEC3B, GATA3, prognosis, DNA damage

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

• Category

  Cancer